Cross Country Healthcare, Inc. (CCRN)
NASDAQ: CCRN · Real-Time Price · USD
13.14
-0.04 (-0.30%)
May 11, 2026, 10:13 AM EDT - Market open
Cross Country Healthcare Stock Forecast
Stock Price Forecast
The 3 analysts that cover Cross Country Healthcare stock have a consensus rating of "Hold" and an average price target of $13.62, which forecasts a 3.65% increase in the stock price over the next year. The lowest target is $9.00 and the highest is $18.61.
Price Target: $13.62 (+3.65%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Cross Country Healthcare stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 1 | 1 | 0 |
| Hold | 3 | 3 | 4 | 2 | 2 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Benchmark | Benchmark | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 8, 2026 |
| Wedbush | Wedbush | Buy → Hold Downgrades $15 → $13 | Buy → Hold | Downgrades | $15 → $13 | +0.84% | May 7, 2026 |
| Wedbush | Wedbush | Hold → Buy Upgrades $11 → $15 | Hold → Buy | Upgrades | $11 → $15 | +14.16% | Mar 19, 2026 |
| Benchmark | Benchmark | Hold → Strong Buy Upgrades $14 | Hold → Strong Buy | Upgrades | $14 | +6.54% | Mar 5, 2026 |
| Wedbush | Wedbush | Hold Initiates $11 | Hold | Initiates | $11 | -16.29% | Feb 3, 2026 |
Financial Forecast
Revenue This Year
996.07M
from 1.05B
Decreased by -5.52%
Revenue Next Year
1.05B
from 996.07M
Increased by 5.01%
EPS This Year
0.11
from -2.93
EPS Next Year
0.28
from 0.11
Increased by 148.98%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.0B | 1.1B | |||
| Avg | 996.1M | 1.0B | |||
| Low | 941.9M | 982.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.5% | 11.1% | |||
| Avg | -5.5% | 5.0% | |||
| Low | -10.7% | -1.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 0.18 | 0.42 | |||
| Avg | 0.11 | 0.28 | |||
| Low | 0.03 | 0.20 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 278.1% | |||
| Avg | - | 149.0% | |||
| Low | - | 76.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.